ClinicalTrials.gg
Active, not recruitingNCT03331198Updated Jul 6, 2026

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

A Phase 1/2 interventional study of JCAR017 (lisocabtagene maraleucel) and JCAR017 (lisocabtagene maraleucel) + ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell and Lymphoma, Small Lymphocytic, sponsored by Juno Therapeutics, a Subsidiary of Celgene. Active, not recruiting at 84 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Juno Therapeutics, a Subsidiary of Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
320
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb — 1 open to participants now, 3 under way, none of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Bristol-Myers Squibb.

Planned enrollment
2nd of 21
320 · median 47
Started
2017
the only one that year
Phase 1/2
4 of 25
none open now
Registered
19th of 25
by date

Among the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb, this one is the 2nd largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2017, is one of 4 in phase 1/2, and was the 19th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. Another separate Phase 1 cohort will assess the combination of JCAR017 and concurrent venetoclax. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.

03

Conditions studied

  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Small Lymphocytic

Keywords

  • TRANSCEND_CLL_004
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of:

    1. CLL with an indication for treatment based on the Investigator's opinion and , or
    2. SLL (lymphadenopathy and/or splenomegaly and \< 5×10\^9 CD19+ CD5+ clonal B lymphocytes/L [\< 5000/µL] in the peripheral blood at diagnosis with measurable disease that is -proven SLL)
  • Subjects (other than those in the ibrutinib + JCAR017 combination therapy and DEME cohort) must have received and failed Bruton tyrosine kinase inhibitor (BTKi) treatment or have been deemed ineligible for BTKi therapy.
  • Subjects in the JCAR017 monotherapy cohorts must have received previous treatment as follows:

    1. Monotherapy cohorts EXCEPT DEME cohort: Subjects with CLL or SLL and high-risk features must have failed at least 2 .
    2. Monotherapy cohorts EXCEPT DEME cohort: Subjects with CLL or SLL and standard-risk features must have failed at least 3 lines of prior therapy.
    3. DEME cohort ONLY: Subjects with CLL or SLL, irrespective of cytogenetic risk features, must have received at least 2 lines of prior therapy including a BTKi and a BCL2i.
  • Subjects in the ibrutinib + JCAR017 combination therapy cohort must either:

    1. be receiving ibrutinib and progressing at the time of study enrollment
    2. be receiving ibrutinib for at least 6 months with a response less than complete response/remission (CR) and have high-risk features as defined in inclusion criterion 5a
    3. have BTK or PLCgamma2 mutations per local laboratory assessment, with or without progression on ibrutinib
    4. have previously received ibrutinib and have no to restarting ibrutinib
  • performance status of ≤ 1
  • Assessed by the Investigator to have adequate bone marrow function to receive lymphodepleting chemotherapy
  • Adequate organ function, defined as:

    1. Serum creatinine ≤ 1.5 × age-adjusted (ULN) OR calculated > 30 mL/min
    2. ≤ 5 × ULN and total \< 2.0 mg/dL (or \< 3.0 mg/dL for subjects with Gilbert's syndrome or leukemic infiltration of the liver)
    3. Adequate pulmonary function, defined as ≤ (CTCAE) Grade 1 dyspnea and saturated oxygen (SaO2) ≥ 92% on room air
    4. Adequate cardiac function, defined as ≥ 40% as assessed by echocardiogram or multiple uptake gated acquisition scan performed within 30 days prior to determination of eligibility
  • Subject either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure.
  • If prior CD19-targeted therapy has been administered, subject must have CD19-positive disease confirmed by immunohistochemistry or flow cytometry since completing the prior CD19-targeted therapy.
  • Subjects in ibrutinib + JCAR017 combination cohort must have progressed on a BTKi and have received prior therapy with venetoclax
  • Subjects in venetoclax + JCAR017 combination cohort must:

    1. have failed at least 1 prior line of therapy, including failed BTKi therapy or have been deemed ineligible to receive BTKi
    2. be venetoclax naive (required for dose expansion) or
    3. if prior venetoclax (only for dose escalation)
    4. have no contraindictions to re-initiation of venetoclax based on prior intolerance and have had at least 6 months elapsed since the last dose of venetoclax, if either, best response was stable disease, or subject experienced disease progression on venetoclax, or within 6 months of venetoclax discontinuation
  • subjects in the venetoclax + JCAR017 combination must have >=9 g/dL, >=500mm3 and >= 75,000/mm3, unless cytopenias are judged by investigator to be due to CLL infiltration of the bone marrow
  • must have diagnosis of CLL or SLL with an indication for treatment based on the investigator's opinion and measurable disease (any of the following measurable lymph nodes ≥1.5 cm in the greatest transverse diameter and/or hepatomegaly or splenomegaly) and demonstration of CLL cells in the peripheral blood by flow cytometry

Exclusion criteria

Exclusion Criteria:

  • Subjects with known active central nervous system (CNS) involvement by . Those with prior CNS disease that has been effectively treated will be eligible if treatment was completed at least 3 months prior to enrollment with no evidence of symptomatic disease and stable abnormalities on repeat imaging.
  • History of another primary malignancy that has not been in remission for at least 2 years. (The following are exempt from the 2-year limit: nonmelanoma skin cancer, completely resected stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, cervical carcinoma in situ on or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected.)
  • Subjects with Richter's transformation
  • Prior treatment with any gene therapy product
  • Active , active , or active (HIV) infection
  • Systemic fungal, bacterial, viral, or other infection that is not controlled
  • Presence of acute or extensive chronic (GVHD)
  • History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other cardiac disease
  • History or presence of clinically relevant CNS pathology such as epilepsy, generalized seizure disorder, aphasia, stroke with current neurologic sequelae, severe brain injuries, dementia, Parkinson's disease, cerebellar disease,cerebral edema, or psychosis
  • Pregnant or nursing (lactating) women
  • Use of any of the following medications or treatments within the noted time prior to leukapheresis:

    1. Alemtuzumab within 6 months prior to leukapheresis
    2. hematopoietic stem cell transplant within 100 days prior to leukapheresis
    3. Cladribine within 3 months prior to leukapheresis
    4. Donor lymphocyte infusions (DLI) within 2 months prior to leukapheresis
    5. Radiation including large bone marrow fields such as sternum or pelvis within 6 weeks prior to leukapheresis
    6. Fludarabine within 4 weeks prior to leukapheresis
    7. GVHD therapies such as calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate mofetil, rapamycin, or antibodies (such as anti-tumor necrosis factor-α [TNFα], anti-interleukin-6 [IL-6], or anti-interleukin-6 receptor [IL 6R]) within 4 weeks prior to leukapheresis
    8. Cyclophosphamide, ifosfamide, bendamustine, chlorambucil, or melphalan within 2 weeks prior to leukapheresis
    9. Therapeutic doses of (defined as > 20 mg/day prednisone or equivalent) within 7 days prior to leukapheresis
    10. Anti-CD20 monoclonal antibodies within 7 days prior to leukapheresis
    11. Venetoclax within 4 days prior to leukapheresis
    12. Idelalisib or duvelisib within 2 days prior to leukapheresis
    13. Lenalidomide or covalent and non-covalent BTKi within 1 day prior to leukapheresis
    14. Experimental agents, including off-label use of approved drugs (with the exception of acalabrutinib which may be continued up to the day before leukapheresis), within 4 weeks prior to leukapheresis unless progression is documented on the experimental therapy and at least 3 half-lives have elapsed prior to leukapheresis
  • Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the Investigator; or subject unwillingness or inability to follow the procedures required in the protocol
  • Progressive vascular tumor invasion, thrombosis, or embolism
  • Deep vein thrombosis or embolism not managed on a stable regimen of anticoagulation
  • Use of any of the following medications or treatments within the noted time prior to leukapheresis lenalidomide or acalabrutinib within 1 day prior to leukapheresis experimental agents, including off-label use of approved drugs, within 4 weeks prior to leukapheresis.
  • Venous thrombosis or embolism requiring treatment but not managed on a stable regimen of anticoagulation
  • For subjects in the venetoclax + JCAR017 combination cohorts only, concomitant treatment with moderate/strong inducers or moderate/strong inhibitors which cannot be discontinued
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    Phase 1 JCAR017 monotherapy

    Subjects will be assigned to receive JCAR017 (lisocabtagene maraleucel)

    Biological: JCAR017 (lisocabtagene maraleucel)

  • Experimental
    Phase 1 JCAR017 + ibrutinib

    Subjects receiving ibrutinib at baseline will be assigned to receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm + ibrutinib

    Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib

  • Experimental
    Phase 2 JCAR017 monotherapy

    Subjects will receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm

    Biological: JCAR017 (lisocabtagene maraleucel)

  • Experimental
    Phase 1 JCAR017 + venetoclax

    Subjects will receive venetoclax as bridging anticancer therapy until lymphodepletion chemotherapy/ JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm. After JCAR017 infusion subjects will receive venetoclax until Day 90.

    Biological: JCAR017 (lisocabtagene maraleucel) + venetoclax

  • Experimental
    Phase 2 JCAR017 Double-Exposed Monotherapy Expansion (DEME)

    Subjects will receive JCAR017 monotherapy

    Biological: JCAR017 (lisocabtagene maraleucel)

Interventions

  • Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.

  • BiologicalJCAR017 (lisocabtagene maraleucel) + ibrutinib

    Drug page: Lisocabtagene maraleucel

    Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.

  • BiologicalJCAR017 (lisocabtagene maraleucel) + venetoclax

    Drug page: Lisocabtagene maraleucel

    Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.

06

What researchers measure

Primary outcomes

  1. Phase 1 JCAR017 monotherapy arm: adverse events

    Proportion of subjects experiencing adverse events

    Time frame: Up to 48 months post treatment

  2. Phase 1 JCAR017 monotherapy arm: laboratory abnormalities

    Proportion of subjects experiencing laboratory abnormalities

    Time frame: Up to 48 months post treatment

  3. Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: adverse events

    Proportion of subjects experiencing adverse events

    Time frame: Up to 48 months post treatment

  4. Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: laboratory abnormalities

    Proportion of subjects experiencing laboratory abnormalities

    Time frame: Up to 48 months post treatment

  5. Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm

    Proportion of subjects who have CR after treatment with JCAR017 + ibrutinib using iwCLL 2018 guidelines

    Time frame: Through post treatment up to Month 48

  6. Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: adverse events

    Proportion of subjects experiencing adverse events

    Time frame: Up to 48 months post treatment

  7. Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: laboratory abnormalities

    Proportion of subjects experiencing laboratory abnormalities

    Time frame: Up to 48 months post treatment

  8. Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm

    Proportion of subjects who have CR after treatment with JCAR017 + venetoclax using iwCLL 2018 guidelines

    Time frame: Through post treatment up to Month 48

  9. Phase 2 JCAR017 monotherapy expansion arm

    Proportion of subjects who have CR after treatment with JCAR017 using iwCLL 2018 guidelines

    Time frame: Through post treatment up to Month 48

  10. Phase 2 JCAR017 Double exposed monotherapy expansion arm: overall response rate (ORR)

    ORR defined as the rate of complete response/remission (CR) \[including complete response/remission with incomplete marrow recovery (Cri)\] plus PR \[including nodular partial response (nPR)\] based on Independent Review Committee (IRC) assessment using International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 guidelines

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: adverse events

    Proportion of subjects experiencing adverse events

    Time frame: Up to 48 months post treatment

  2. Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: laboratory abnormalities

    Proportion of subjects experiencing laboratory abnormalities

    Time frame: Up to 48 months post treatment

  3. Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: ORR

    Defined as the rate of CR (including CRi)

    Time frame: Up to 48 months post treatment

  4. Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: MRD negative response rate in peripheral blood

    Proportion of subjects who achieve MRD CR

    Time frame: Up to 48 months post treatment

  5. Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: MRD-negative CR rate in peripheral blood

    Proportion of subjects who achieve MRD CR

    Time frame: Up to 48 months post treatment

  6. Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Duration of response (DOR)

    Defined as the time from first response (CR, CRi, nPR, or PR) to the earlier date of PD or death due to any cause

    Time frame: Up to 48 months post treatment

  7. Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Duration of complete response (DoCR)

    Defined as the time from first CR or CRi to the earlier date of PD or death due to any cause

    Time frame: Up to 48 months post treatment

  8. Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Time to response (TTR)

    Defined as the interval from JCAR017 infusion to the first documentation of CR, CRi, nPR, or PR

    Time frame: Up to 48 months post treatment

  9. Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Time to complete response (TTCR)

    Defined as the interval from JCAR017 infusion to the first documentation of CR

    Time frame: Up to 48 months post treatment

  10. Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: PFS

    Defined as the time from JCAR017 infusion to the earlier date of PD or death due to any cause

    Time frame: Up to 48 months post treatment

  11. Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: OS

    Defined as the time from JCAR017 infusion to the date of death due to any cause

    Time frame: Up to 48 months post treatment

  12. Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: adverse events

    Proportion of subject experiencing adverse events

    Time frame: Up to 48 months post treatment

  13. Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: lab abnormalities

    Proportion of subjects experiencing laboratory abnormalities

    Time frame: Up to 48 months post treatment

  14. Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: ORR

    Defined as the rate of CR (including CRi)

    Time frame: Through post treatment Day 90

  15. Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: MRD-negative response rate in peripheral blood

    Proportion of subjects who achieve MRD CR

    Time frame: Up to 48 months post treatment

  16. Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: MRD-negative CR rate in peripheral blood

    Proportion of subjects who achieve MRD CR

    Time frame: Through post treatment Day 90

  17. Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Duration of response (DOR)

    Defined as the time from first response (CR, CRi, nPR, or PR) to the earlier date of PD or death due to any cause

    Time frame: Up to 48 months post treatment

  18. Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Duration of complete response (DoCR)

    Defined as the time from first CR or CRi to the earlier date of PD or death due to any cause

    Time frame: Up to 48 months post treatment

  19. Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Time to response (TTR)

    Defined as the interval from JCAR017 infusion to the first documentation of CR, CRi, nPR, or PR

    Time frame: Up to 48 months post treatment

  20. Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Time to complete response (TTCR)

    Defined as the interval from JCAR017 infusion to the first documentation of CR

    Time frame: Up to 48 months post treatment

  21. Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: PFS

    Defined as the time from JCAR017 infusion to the earlier date of PD or death due to any cause

    Time frame: Up to 48 months post treatment

  22. Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: OS

    Defined as the time from JCAR017 infusion to the date of death due to any cause

    Time frame: Up to 48 months post treatment

  23. Phase 2 JCAR017 Monotherapy Expansion Arm: adverse events

    Proportion of subjects experiencing adverse events

    Time frame: Up to 48 months post treatment

  24. Phase 2 JCAR017 Monotherapy Expansion Arm: laboratory abnormalities

    Proportion of subjects experiencing laboratory abnormalities

    Time frame: Up to 48 months post treatment

  25. Phase 2 JCAR017 Monotherapy Expansion Arm: ORR

    Defined as the rate of CR (including CRi)

    Time frame: Up to 48 months post treatment

  26. Phase 2 JCAR017 Monotherapy Expansion Arm: MRD negative response rate in peripheral blood

    Proportion of subjects who achieve MRD CR

    Time frame: Up to 48 months post treatment

  27. Phase 2 JCAR017 Monotherapy Expansion Arm: MRD-negative CR rate in peripheral blood

    Proportion of subjects who achieve MRD CR

    Time frame: Up to 48 months post treatment

  28. Phase 2 JCAR017 Monotherapy Expansion Arm: Duration of response (DOR)

    Defined as the time from first response (CR, CRi, nPR, or PR) to the earlier date of PD or death due to any cause

    Time frame: Up to 48 months post treatment

  29. Phase 2 JCAR017 Monotherapy Expansion Arm: Duration of complete response (DoCR)

    Defined as the time from first CR or CRi to the earlier date of PD or death due to any cause

    Time frame: Up to 48 months post treatment

  30. Phase 2 JCAR017 Monotherapy Expansion Arm: Time to response (TTR)

    Defined as the interval from JCAR017 infusion to the first documentation of CR, CRi, nPR, or PR

    Time frame: Up to 48 months post treatment

  31. Phase 2 JCAR017 Monotherapy Expansion Arm: Time to complete response (TTCR)

    Defined as the interval from JCAR017 infusion to the first documentation of CR

    Time frame: Up to 48 months post treatment

  32. Phase 2 JCAR017 Monotherapy Expansion Arm: PFS

    Defined as the time from JCAR017 infusion to the earlier date of PD or death due to any cause

    Time frame: Up to 48 months post treatment

  33. Phase 2 JCAR017 Monotherapy Expansion Arm: OS

    Defined as the time from JCAR017 infusion to the date of death due to any cause

    Time frame: Up to 48 months post treatment

  34. Phase 2 JCAR017 Monotherapy Expansion Arm: Health-related quality of life (HRQoL) questionnaire

    Change from baseline in HRQoL assessed using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30

    Time frame: Up to 48 months post treatment

  35. Phase 2 JCAR017 Monotherapy Expansion Arm: HRQoL questionnaire

    Change from baseline in HRQoL assessed using the EORTC chronic lymphocytic leukemia (CLL)-specific module QLQ-CLL-17

    Time frame: Up to 48 months post treatment

  36. Phase 2 JCAR017 Monotherapy Expansion Arm: Health economics and outcomes research (HEOR) questionnaire

    Change from baseline in measurement of health utility values using EuroQol instrument EQ-5D-5L

    Time frame: Up to 48 months post treatment

  37. Phase 2 JCAR017 Monotherapy Expansion Arm: HEOR questionnaire

    Proportion of participants with intensive care unit (ICU) inpatient days

    Time frame: Up to 48 months post treatment

  38. Phase 2 JCAR017 Monotherapy Expansion Arm: HEOR questionnaire

    Proportion of participants with non-ICU inpatient days

    Time frame: Up to 48 months post treatment

  39. Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: adverse events

    Proportion of subjects experiencing adverse events

    Time frame: Up to approximately 24 months

  40. Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: laboratory abnormalities

    Proportion of subjects experiencing laboratory abnormalities

    Time frame: Up to approximately 24 months

  41. Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Duration of response (DOR)

    Defined as the time from first response (CR, CRi, nPR, or PR) to the earlier date of PD or death due to any cause

    Time frame: Up to approximately 24 months

  42. Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: CR rate

    Defined as the rate of CR (including CRi) based on IRC assessment using iwCLL 2018 guidelines

    Time frame: Up to approximately 24 months

  43. Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: MRD-negative response rate in peripheral blood

    Proportion of subjects who achieve MRD negative status

    Time frame: Up to approximately 24 months

  44. Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: MRD-negative CR rate in peripheral blood

    Proportion of subjects who achieve MRD-negative CR

    Time frame: Up to approximately 24 months

  45. Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Time to response (TTR)

    Defined as the interval from JCAR017 infusion to the first documentation of CR, CRi, nPR, or PR

    Time frame: Up to approximately 24 months

  46. Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Time to complete response (TTCR)

    Define as the interval from JCAR017 infusion to the first documentation of CR

    Time frame: Up to approximately 24 months

  47. Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Progression free survival (PFS)

    Defined as the time from JCAR017 infusion to the earlier date of PD or death due to any cause

    Time frame: Up to approximately 24 months

  48. Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Overall Survival (OS)

    Defined as the time from JCAR017 infusion to the date of death due to any cause

    Time frame: Up to approximately 24 months

07

Study locations

84 sites
  • Local Institution - 0006
    Birmingham, Alabama 35294, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Local Institution - 0043
    Gilbert, Arizona 85234, United States
  • City of Hope
    Duarte, California 91010, United States
  • Local Institution - 0007
    Duarte, California 91010, United States
  • Local Institution - 0025
    La Jolla, California 92093, United States
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • Local Institution - 0059
    Los Angeles, California 90095, United States
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Local Institution - 0010
    San Francisco, California 94143, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Local Institution - 0111
    Denver, Colorado 80218, United States
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
  • Local Institution - 0085
    Washington D.C., District of Columbia 20007, United States
  • Local Institution - 0080
    Jacksonville, Florida 32224, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Local Institution - 0104
    Atlanta, Georgia 30322, United States
  • Local Institution - 0019
    Atlanta, Georgia 30342, United States
  • The Blood and Marrow Transplant Group of Georgia (BMTGA)
    Atlanta, Georgia 30342, United States
  • Local Institution - 0003
    Chicago, Illinois 60611, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Local Institution - 0016
    Chicago, Illinois 60637, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Local Institution - 0105
    Indianapolis, Indiana 46237, United States
  • Local Institution - 0107
    Wichita, Kansas 67124, United States
  • Local Institution - 0064
    Louisville, Kentucky 40202, United States
  • Local Institution - 0027
    New Orleans, Louisiana 70112, United States
  • Local Institution - 0005
    Boston, Massachusetts 02114, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Local Institution - 0015
    Boston, Massachusetts 02215, United States
  • University of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109-5362, United States
  • Local Institution - 0084
    Ann Arbor, Michigan 48109, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Local Institution - 0062
    Detroit, Michigan 48201, United States
  • Local Institution - 0109
    Detroit, Michigan 48202, United States
  • Local Institution - 0054
    Rochester, Minnesota 55905, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Local Institution - 0008
    Omaha, Nebraska 68198, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Local Institution - 0001
    Basking Ridge, New Jersey 07920, United States
  • Local Institution - 0114
    Edison, New Jersey 08820, United States
  • Local Institution - 0038
    Hackensack, New Jersey 07601-2191, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0106
    Morristown, New Jersey 07960, United States
  • Local Institution - 0077
    New Brunswick, New Jersey 08903, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • Local Institution - 0035
    New York, New York 10021, United States
  • Local Institution - 0026
    New York, New York 10032, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Local Institution - 0089
    Stony Brook, New York 11794-8160, United States
  • Local Institution - 0120
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0030
    Durham, North Carolina 27705, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Local Institution - 0118
    Winston-Salem, North Carolina 27157, United States
  • University Hospitals Seidman Cancer Center (Case Western)
    Cleveland, Ohio 44106-5061, United States
  • Local Institution - 0078
    Cleveland, Ohio 44106, United States
  • Local Institution - 0031
    Columbus, Ohio 43210, United States
  • Local Institution - 0082
    Oklahoma City, Oklahoma 73104, United States
  • University of Oklahoma Health Sciences Center (Stephenson Cancer Center)
    Oklahoma City, Oklahoma 73104, United States
  • Local Institution - 0098
    Eugene, Oregon 97401, United States
  • Local Institution - 0088
    Philadelphia, Pennsylvania 19104, United States
  • University of Pennsylvania Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 0032
    Philadelphia, Pennsylvania 19107, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Local Institution - 0029
    Pittsburgh, Pennsylvania 15232, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Local Institution - 0117
    Chattanooga, Tennessee 37403, United States
  • Local Institution - 0119
    Nashville, Tennessee 37203, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Local Institution - 0083
    Dallas, Texas 75390, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Local Institution - 0079
    Dallas, Texas 75426, United States
  • Local Institution - 0002
    Houston, Texas 77030, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Local Institution - 0028
    Salt Lake City, Utah 84112, United States
  • Local Institution - 0087
    Richmond, Virginia 23298, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Local Institution - 0018
    Seattle, Washington 98109, United States
  • Local Institution - 0055
    Milwaukee, Wisconsin 53226, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Local Institution - 0112
    Toronto, Ontario M5G 2C1, Canada
08

References and documents

Publications

  • Wierda WG, Dorritie KA, Gauthier J, Nath R, Kipps TJ, Riedell PA, Eradat HA, Kenderian SS, Kharfan-Dabaja MA, Shah NN, Solomon SR, Stephens DM, Ermann DA, Arnason JE, Deol A, Feldman TA, Andreadis CB, Ghosh M, Ma S, Schuster SJ, Gergis U, Vose JM, Soumerai JD, van Besien K, Tuazon SA, Perna SK, Ou SS, Ananthakrishnan R, Rane N, Papp E, Ansari S, Thompson EG, Okal A, Peiser L, Chen Y, Sengupta S, Ray PR, Wang J, Siddiqi T. Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. Blood. 2026 Jul 28:blood.2026033565. doi: 10.1182/blood.2026033565. Online ahead of print. PubMed 42520199 ↗
  • Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 Aug 19;402(10402):641-654. doi: 10.1016/S0140-6736(23)01052-8. Epub 2023 Jun 6. PubMed 37295445 ↗
  • Teoh J, Brown LF. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. Cytotherapy. 2022 Sep;24(9):962-973. doi: 10.1016/j.jcyt.2022.03.013. Epub 2022 May 21. PubMed 35610089 ↗
  • Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 Mar 24;139(12):1794-1806. doi: 10.1182/blood.2021011895. PubMed 34699592 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2017 (actual). Primary completion is estimated for Nov 2027, 119 months after the start.

Of 50 industry-sponsored phase 1/2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 104. This study's planned 119 months is above that.

Counting every sponsor, half of 90 studies reached it within 78 months; a quarter within 51 and three quarters within 103.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2017
First posted
Nov 6, 2017
StartActual
Nov 27, 2017
Primary completionEst.
Nov 26, 2027
CompletionEst.
Nov 26, 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03331198
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Nov 27, 2017
Primary completion
Nov 26, 2027 (estimated)
Completion
Nov 26, 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisocabtagene maraleucel

Start the discussion